Publications
Publishing the Frontiers of Immuno-Oncology
Spotlight Publication
Botensilimab (Fc-enhanced anti-CTLA-4), Balstilimab (PD-1 inhibitor)
Emerging survival plateaus with botensilimab and balstilimab: Pan tumor data from a large phase 1b trial of advanced solid tumors
Oct 17, 2025
,
Gordon et al.
ESMO
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
INCAGN1876 (GITR Agonist)
INCAGN1876, a Unique GITR Agonist Antibody That Facilitates GITR Oligomerization.
AACR
American Association for Cancer Research (AACR)
June 2, 2022
,
Gonzalez, et al.
No items found.
INCAGN1949 (OX40 Agonist)
INCAGN1949, an Anti-OX40 Antibody With an Optimal Agonistic Profile and the Ability to Selectively Deplete Intratumoral Regulatory T Cells
AACR
American Association for Cancer Research (AACR)
June 2, 2022
,
Gonzalez, et al.
No items found.
AGENT-797 (Allogeneic iNKT Cell Therapy)
TCR Fingerprinting and Off-Target Peptide Identification.
Other Articles & Publications
Frontiers in Immunology
June 2, 2022
,
Karapetyan, et al.
No items found.
AGENT-797 (Allogeneic iNKT Cell Therapy)
TCR Fingerprinting and Off-Target Peptide Identification.
SITC
Society for Immunotherapy of Cancer (SITC)
June 2, 2022
,
Karapetyan, et al.
No items found.